Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 5/20 | 1.00 |
| ▸ | PHLPP2 | Q6ZVD8 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 4/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | BLVRB | P30043 | 2/20 | 0.72 |
| ▸ | PDE4A | P27815 | 1/20 | 0.72 |
| ▸ | KDR | P35968 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.69 |
| ▸ | APP | P05067 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salazosulfamide SCHEMBL6432001 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1PHLPP2ALDH1A1CYP2C9 | |
| Salazosulfamide SCHEMBL11884576 | 0.91 | PHLPP2 (0.82) | PTGS2PTGS1PHLPP2ALDH1A1CYP2C9 | |
| SCHEMBL14596773 | 0.88 | PHLPP2 (0.78) | PTGS2PTGS1PHLPP2ALDH1A1CYP2C9 | |
| SCHEMBL6250400 | 0.88 | PHLPP2 (0.78) | PTGS2PTGS1PHLPP2ALDH1A1CYP2C9 | |
| SCHEMBL5576043 | 0.88 | PHLPP2 (0.78) | PTGS2PTGS1PHLPP2ALDH1A1CYP2C9 | |
| SCHEMBL30604557 | 0.88 | PHLPP2 (0.78) | PTGS2PTGS1PHLPP2ALDH1A1CYP2C9 | |
| Olsalazine SCHEMBL5922630 | 0.87 | MEN1 (0.96) | PTGS2PTGS1PHLPP2ALDH1A1CYP2C9 | |
| SCHEMBL27727542 | 0.86 | PHLPP2 (0.76) | PTGS2PTGS1PHLPP2ALDH1A1CYP2C9 | |
| Olsalazine SCHEMBL25119 | 0.85 | MEN1 (1.00) | PTGS2PTGS1PHLPP2ALDH1A1CYP2C9 | |
| Olsalazine SCHEMBL25118 | 0.85 | MEN1 (1.00) | PTGS2PTGS1PHLPP2ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101277684-A | Microparticles for the modified release of at least one active principle and oral pharmaceutical forms containing them | FLAMEL TECH SA (FR) | 2008-10-01 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| CN-101237838-A | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX INC (US) | 2008-08-06 | — | — | CN | claimed |
| CN-101203509-A | Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORP (US) | 2008-06-18 | — | — | CN | claimed |
| CN-101189238-A | Piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORP (US) | 2008-05-28 | — | — | CN | claimed |
| CN-101189225-A | Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORP (US) | 2008-05-28 | — | — | CN | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| US-6159585-A | Security paper | GEORGIA-PACIFIC CORPORATION (US) | 2000-12-12 | — | — | US | claimed |
| WO-1998041688-A1 | SECURITY PAPER | GEORGIA-PACIFIC CORPORATION, INC. (US) | 1998-09-24 | — | — | WO | claimed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | disclosed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | PTGS2 2698/4885PTGS1 2771/4885PHLPP2 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.